Biophytis Announces New Scientific Advisory Board for Phase 2 Obesity Study

Biophytis SA, a biotechnology company focusing on age-related diseases, has formed a new Scientific Advisory Board for its upcoming phase 2 clinical study in obesity treatment, known as the OBA study. The advisory board includes notable experts such as Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain. The study will examine the efficacy of BIO101 in combination with GLP1-RA in preserving muscle mass during weight loss in obese patients.

The company, based in Paris, France, and Cambridge, USA, aims to file an Investigational New Drug (IND) application with the FDA within the upcoming weeks. This will facilitate the commencement of the phase 2 study in the USA. Biophytis' CEO, Stanislas Veillet, highlighted the credentials of the new board members, emphasizing their extensive experience in obesity and internal medicine which is expected to significantly contribute to the development program.